| 2026-09-11 17:00 |
8-K |
["8.01"] |
other |
0.05
|
Routine shares outstanding update from warrant exercise and restricted stock issuance; no M&A signals. |
SEC · detail |
| 2026-09-09 08:50 |
8-K |
["7.01", "8.01", "9.01"] |
other |
0.05
|
FDA 510(k) submission announcement for drug screening system; no M&A implications. |
SEC · detail |
| 2026-09-02 17:00 |
8-K |
["1.01"] |
other |
0.05
|
Private placement equity financing with warrants; no M&A signals detected. |
SEC · detail |
| 2026-09-01 17:10 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine 8-K disclosing product study results; no M&A signals detected. |
SEC · detail |
| 2026-08-28 17:20 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine investor presentation disclosure with no M&A-related language or strategic transaction indicators. |
SEC · detail |
| 2026-08-19 08:50 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine quarterly earnings announcement with no M&A-related content or signals. |
SEC · detail |
| 2026-08-11 17:29 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine regulatory announcement of FDA study completion; no M&A signals present. |
SEC · detail |
| 2026-08-05 08:55 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine product development announcement; no M&A, strategic review, or transaction indicators present. |
SEC · detail |
| 2026-08-03 17:22 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
8-K disclosure of completion of Interference Study for drug screening system; no M&A signals. |
SEC · detail |
| 2026-08-03 17:20 |
8-K |
["8.01"] |
other |
0.05
|
Routine share count update from ATM offering, warrant exercises, and restricted stock issuance. No M&A signal. |
SEC · detail |
| 2026-07-23 17:00 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine FDA 510(k) submission progress disclosure; no M&A signals present. |
SEC · detail |
| 2026-07-21 08:50 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine disclosure of FDA 510(k) submission progress; no M&A signals present. |
SEC · detail |
| 2026-06-16 16:30 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine regulatory disclosure regarding FDA 510(k) submission progress for drug screening device; no M&A signals. |
SEC · detail |
| 2026-06-02 08:48 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine 8-K disclosing FDA 510(k) study initiation; no M&A signals present. |
SEC · detail |
| 2026-05-13 21:08 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine earnings announcement with no M&A indicators or transaction signals. |
SEC · detail |